The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Blenrep (belantamab mafodotin-blmf), a first-in-class treatment for heavily pretreated adults with relapsed or refractory multiple myeloma, its developer, GlaxoSmithKline, announced. The approval is specific for people who have been given at least four previous therapies, including a CD38 inhibitor, a proteasome inhibitor, and an immunomodulatory treatment. It follows last month’s recommendation from the FDA’s Oncologic Drugs Advisory Committee. Accelerated approval is a form of conditional approval…
You must be logged in to read/download the full post.
The post FDA Approves Blenrep, 1st of Its Kind, for Heavily Pretreated Multiple Myeloma appeared first on BioNewsFeeds.